Mara Artibani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mara Artibani has a total of 167 co-authors. Here are the top co-authors by number of shared publications:
- Zhiyuan Hu
Frontier Science Center for Immunology and Metabolism, Medical Research Institute, Wuhan University, Wuhan, China
16 shared publications - Ahmed Ashour Ahmed
MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
12 shared publications - Christopher Yau
Nuffield Department for Women's and Reproductive Health, University of Oxford, Oxford, UK.
10 shared publications - Ahwan Pandey
Peter MacCallum Cancer Centre, Melbourne, Australia
8 shared publications - Alistair Easton
Department of Oncology, University of Oxford, Oxford, United Kingdom
8 shared publications - Amro Ahmed-Ebbiary
MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
8 shared publications
Latest Publications
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Oxford Classic–Defined EMT Risk Stratification of High-Grade Serous Ovarian Cancer for Guiding Treatment Decisions
Supplementary Fig. S1. [A] Violin plot illustrating the distribution of OxC-EMT scores in 12 independent datasets. [B] Line graph of Hazard Ratios and associated p-values derived from fitting a loop structured cox regression model to the combined set. Y-axis on the left-hand side represents the scale for Hazard Ratio and the y-axis on the right-hand side represents the scale for the p-value. [C] Plot displaying median survival time (in days) for OxC-EMT-high (solid red line) and corresponding 95% CI (dashed red line) and median survival for OxC-EMT-low (solid blue line) and corresponding 95% CI (dashed blue line). [D] Kaplan-Meier survival plot demonstrating the probability of overall survival for OxC-EMT-high/BRCAmutated, OxC-EMT-high/BRCAwildtype, OxC-EMT-low/BRCAmutated and OxC-EMT-low/BRCAwildtype patients in the Scottish cohort. [E] Kaplan-Meier survival plot demonstrating the probability of overall survival for OxC-EMT-low risk patients in the Combined set with Oxford Classic subtypes, Cell Cycle, Differentiated, KRT17 and Mixed.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Oxford Classic–Defined EMT Risk Stratification of High-Grade Serous Ovarian Cancer for Guiding Treatment Decisions
Supplementary Fig. S1. [A] Violin plot illustrating the distribution of OxC-EMT scores in 12 independent datasets. [B] Line graph of Hazard Ratios and associated p-values derived from fitting a loop structured cox regression model to the combined set. Y-axis on the left-hand side represents the scale for Hazard Ratio and the y-axis on the right-hand side represents the scale for the p-value. [C] Plot displaying median survival time (in days) for OxC-EMT-high (solid red line) and corresponding 95% CI (dashed red line) and median survival for OxC-EMT-low (solid blue line) and corresponding 95% CI (dashed blue line). [D] Kaplan-Meier survival plot demonstrating the probability of overall survival for OxC-EMT-high/BRCAmutated, OxC-EMT-high/BRCAwildtype, OxC-EMT-low/BRCAmutated and OxC-EMT-low/BRCAwildtype patients in the Scottish cohort. [E] Kaplan-Meier survival plot demonstrating the probability of overall survival for OxC-EMT-low risk patients in the Combined set with Oxford Classic subtypes, Cell Cycle, Differentiated, KRT17 and Mixed.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Data from Oxford Classic–Defined EMT Risk Stratification of High-Grade Serous Ovarian Cancer for Guiding Treatment Decisions
Purpose:The association between epithelial-to-mesenchymal transition (EMT) in high-grade serous ovarian cancer (HGSOC) and poor prognosis is known. However, molecularly defining a subset of tumors that reproducibly associates with poor prognosis has been an elusive goal in this disease. A molecular signature that can robustly identify patients with poor prognosis and guide treatment decisions, including surgical strategy and targeted therapies, can improve survival rates.Experimental Design:We carried out RNA sequencing of 139 tumor samples (Brescia cohort); an external validation on 362 and 126 patients from the Scottish and Garsed cohorts, respectively; and a meta-analysis of 1,023 tumors to develop clinically useful risk groups. Identification of therapeutic targets was carried out by transcriptomic analyses of fluorescence-activated cell sorted (FACS) tumor epithelial cells and multiplex immunofluorescence assessment of tissue sections.Results:In this study, we have validated the prognostic strength of the Oxford Classic–defined EMT in three independent patient cohorts: Brescia [HR = 3.6; 95% confidence interval (CI) of 1.59–7.97; P = 1.99e−03], Scottish (HR = 1.71; 95% CI of 1.08–2.70; P = 2.23e−02), and Garsed (Kruskal–Wallis P = 0.00071). OxC-based risk stratification of HGSOC could robustly identify poor-risk patients with a 5-year median survival for OxC high-risk and OxC low-risk groups of 13% and 50%, respectively (95% CI of 7.1%–23.5% vs. 36.1%–69.3%) in the Brescia cohort. Further analysis of the risk groups suggests that an alternative surgical strategy and a combination therapy involving EMT targeting drugs and immunomodulators could elicit improved clinical response in poor-risk patients.Conclusions:This study provides a clinically useful risk stratification strategy for HGSOC, as well as targeted treatment options for high-risk patients.See related commentary by Venegas et al., p. 10
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Oxford Classic–Defined EMT Risk Stratification of High-Grade Serous Ovarian Cancer for Guiding Treatment Decisions
Purpose:The association between epithelial-to-mesenchymal transition (EMT) in high-grade serous ovarian cancer (HGSOC) and poor prognosis is known. However, molecularly defining a subset of tumors that reproducibly associates with poor prognosis has been an elusive goal in this disease. A molecular signature that can robustly identify patients with poor prognosis and guide treatment decisions, including surgical strategy and targeted therapies, can improve survival rates.Experimental Design:We carried out RNA sequencing of 139 tumor samples (Brescia cohort); an external validation on 362 and 126 patients from the Scottish and Garsed cohorts, respectively; and a meta-analysis of 1,023 tumors to develop clinically useful risk groups. Identification of therapeutic targets was carried out by transcriptomic analyses of fluorescence-activated cell sorted (FACS) tumor epithelial cells and multiplex immunofluorescence assessment of tissue sections.Results:In this study, we have validated the prognostic strength of the Oxford Classic–defined EMT in three independent patient cohorts: Brescia [HR = 3.6; 95% confidence interval (CI) of 1.59–7.97; P = 1.99e−03], Scottish (HR = 1.71; 95% CI of 1.08–2.70; P = 2.23e−02), and Garsed (Kruskal–Wallis P = 0.00071). OxC-based risk stratification of HGSOC could robustly identify poor-risk patients with a 5-year median survival for OxC high-risk and OxC low-risk groups of 13% and 50%, respectively (95% CI of 7.1%–23.5% vs. 36.1%–69.3%) in the Brescia cohort. Further analysis of the risk groups suggests that an alternative surgical strategy and a combination therapy involving EMT targeting drugs and immunomodulators could elicit improved clinical response in poor-risk patients.Conclusions:This study provides a clinically useful risk stratification strategy for HGSOC, as well as targeted treatment options for high-risk patients.See related commentary by Venegas et al., p. 10
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Oxford Classic–Defined EMT Risk Stratification of High-Grade Serous Ovarian Cancer for Guiding Treatment Decisions
Supplementary Fig. S3. [A] Horizontal bar chart representing disease enrichment analysis of 404 differentially expressed genes. [B] Bar chart illustrating a subset of 404 genes that have been previously described in other cancer types. [C] Forest plot illustrating hazard ratio from univariable cox regression analysis, 95% CI and p-value for Overall survival of OxC-EMT score in eight cancer types.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Oxford Classic–Defined EMT Risk Stratification of High-Grade Serous Ovarian Cancer for Guiding Treatment Decisions
Supplementary Fig. S3. [A] Horizontal bar chart representing disease enrichment analysis of 404 differentially expressed genes. [B] Bar chart illustrating a subset of 404 genes that have been previously described in other cancer types. [C] Forest plot illustrating hazard ratio from univariable cox regression analysis, 95% CI and p-value for Overall survival of OxC-EMT score in eight cancer types.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Oxford Classic–Defined EMT Risk Stratification of High-Grade Serous Ovarian Cancer for Guiding Treatment Decisions
Supplementary Fig. S2. Volcano plot illustrating genes that are differentially expressed in OxC-EMT>0.5 compared to OxC-EMT = 0 in [A] Brescia cohort, [B] TCGA dataset [C] AOCS dataset [D] OVCAD dataset.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Oxford Classic–Defined EMT Risk Stratification of High-Grade Serous Ovarian Cancer for Guiding Treatment Decisions
Supplementary Fig. S2. Volcano plot illustrating genes that are differentially expressed in OxC-EMT>0.5 compared to OxC-EMT = 0 in [A] Brescia cohort, [B] TCGA dataset [C] AOCS dataset [D] OVCAD dataset.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Oxford Classic–Defined EMT Risk Stratification of High-Grade Serous Ovarian Cancer for Guiding Treatment Decisions
Supplementary Table S1. [Worksheet-1] List of differentially expressed genes in OxC-EMT-high compared to OxC-EMT-low bulk tumour samples from patients in the Brescia, TCGA, AOCS and OVCAD cohorts. [Worksheet-2] List of differentially expressed genes in OxC-EMT-high compared to OxC-EMT-low tumour epithelial cells.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Oxford Classic–Defined EMT Risk Stratification of High-Grade Serous Ovarian Cancer for Guiding Treatment Decisions
Supplementary Table S1. [Worksheet-1] List of differentially expressed genes in OxC-EMT-high compared to OxC-EMT-low bulk tumour samples from patients in the Brescia, TCGA, AOCS and OVCAD cohorts. [Worksheet-2] List of differentially expressed genes in OxC-EMT-high compared to OxC-EMT-low tumour epithelial cells.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Oxford Classic–Defined EMT Risk Stratification of High-Grade Serous Ovarian Cancer for Guiding Treatment Decisions
Supplementary Fig. S4. [A] FACS images of DAPI-negative live cells from which EpCAM+ALDH+cells (EpCAM-sc) and rest of EpCAM+cells (EpCAM-bulk) were isolated from tumour tissue of patients, 11611, 11617, 11619 and 11624. All EpCAM+ cells were isolated from tumour tissue of patient 11641. Representative images of TGFβ1 and TGFβ3 expression by mIF in [B] OxC-EMT-high tumour (patient-BS14) and [C] OxC-EMT-low tumour (patient-BS141).
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Oxford Classic–Defined EMT Risk Stratification of High-Grade Serous Ovarian Cancer for Guiding Treatment Decisions
Supplementary Fig. S4. [A] FACS images of DAPI-negative live cells from which EpCAM+ALDH+cells (EpCAM-sc) and rest of EpCAM+cells (EpCAM-bulk) were isolated from tumour tissue of patients, 11611, 11617, 11619 and 11624. All EpCAM+ cells were isolated from tumour tissue of patient 11641. Representative images of TGFβ1 and TGFβ3 expression by mIF in [B] OxC-EMT-high tumour (patient-BS14) and [C] OxC-EMT-low tumour (patient-BS141).
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Oxford Classic–Defined EMT Risk Stratification of High-Grade Serous Ovarian Cancer for Guiding Treatment Decisions
Supplementary Fig. S5. Representative images of an [A] OxC-EMT-high (patient BS137) and [B] OxC-EMT-low (patient BS141) tumour from the validation mIF experiments. [C] Violin plots demonstrating the difference in the abundance of M2 macrophages (CD206+ or CD206+CD163+) and CD8+TRM using immune cell counts normalised against total number of nuclei in each ROI.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Oxford Classic–Defined EMT Risk Stratification of High-Grade Serous Ovarian Cancer for Guiding Treatment Decisions
Supplementary Fig. S5. Representative images of an [A] OxC-EMT-high (patient BS137) and [B] OxC-EMT-low (patient BS141) tumour from the validation mIF experiments. [C] Violin plots demonstrating the difference in the abundance of M2 macrophages (CD206+ or CD206+CD163+) and CD8+TRM using immune cell counts normalised against total number of nuclei in each ROI.
- 24 July 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (1) , 188-202
Oxford Classic–Defined EMT Risk Stratification of High-Grade Serous Ovarian Cancer for Guiding Treatment Decisions
Purpose: The association between epithelial-to-mesenchymal transition (EMT) in high-grade serous ovarian cancer (HGSOC) and poor prognosis is known. However, molecularly defining a subset of tumors that reproducibly associates with poor prognosis has been an elusive goal in this disease. A molecular signature that can robustly identify patients with poor prognosis and guide treatment decisions, including surgical strategy and targeted therapies, can improve survival rates. Experimental Design: We carried out RNA sequencing of 139 tumor samples (Brescia cohort); an external validation on 362 and 126 patients from the Scottish and Garsed cohorts, respectively; and a meta-analysis of 1,023 tumors to develop clinically useful risk groups. Identification of therapeutic targets was carried out by transcriptomic analyses of fluorescence-activated cell sorted (FACS) tumor epithelial cells and multiplex immunofluorescence assessment of tissue sections. Results: In this study, we have validated the prognostic strength of the Oxford Classic–defined EMT in three independent patient cohorts: Brescia [HR = 3.6; 95% confidence interval (CI) of 1.59–7.97; P = 1.99e−03], Scottish (HR = 1.71; 95% CI of 1.08–2.70; P = 2.23e−02), and Garsed (Kruskal–Wallis P = 0.00071). OxC-based risk stratification of HGSOC could robustly identify poor-risk patients with a 5-year median survival for OxC high-risk and OxC low-risk groups of 13% and 50%, respectively (95% CI of 7.1%–23.5% vs. 36.1%–69.3%) in the Brescia cohort. Further analysis of the risk groups suggests that an alternative surgical strategy and a combination therapy involving EMT targeting drugs and immunomodulators could elicit improved clinical response in poor-risk patients. Conclusions: This study provides a clinically useful risk stratification strategy for HGSOC, as well as targeted treatment options for high-risk patients. See related commentary by Venegas et al., p. 10
- 24 July 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (1) , 188-202
Oxford Classic–Defined EMT Risk Stratification of High-Grade Serous Ovarian Cancer for Guiding Treatment Decisions
Purpose: The association between epithelial-to-mesenchymal transition (EMT) in high-grade serous ovarian cancer (HGSOC) and poor prognosis is known. However, molecularly defining a subset of tumors that reproducibly associates with poor prognosis has been an elusive goal in this disease. A molecular signature that can robustly identify patients with poor prognosis and guide treatment decisions, including surgical strategy and targeted therapies, can improve survival rates. Experimental Design: We carried out RNA sequencing of 139 tumor samples (Brescia cohort); an external validation on 362 and 126 patients from the Scottish and Garsed cohorts, respectively; and a meta-analysis of 1,023 tumors to develop clinically useful risk groups. Identification of therapeutic targets was carried out by transcriptomic analyses of fluorescence-activated cell sorted (FACS) tumor epithelial cells and multiplex immunofluorescence assessment of tissue sections. Results: In this study, we have validated the prognostic strength of the Oxford Classic–defined EMT in three independent patient cohorts: Brescia [HR = 3.6; 95% confidence interval (CI) of 1.59–7.97; P = 1.99e−03], Scottish (HR = 1.71; 95% CI of 1.08–2.70; P = 2.23e−02), and Garsed (Kruskal–Wallis P = 0.00071). OxC-based risk stratification of HGSOC could robustly identify poor-risk patients with a 5-year median survival for OxC high-risk and OxC low-risk groups of 13% and 50%, respectively (95% CI of 7.1%–23.5% vs. 36.1%–69.3%) in the Brescia cohort. Further analysis of the risk groups suggests that an alternative surgical strategy and a combination therapy involving EMT targeting drugs and immunomodulators could elicit improved clinical response in poor-risk patients. Conclusions: This study provides a clinically useful risk stratification strategy for HGSOC, as well as targeted treatment options for high-risk patients. See related commentary by Venegas et al., p. 10
- Open Access
- 27 April 2023
- Published by Wiley in Health Science Reports
- Vol. 6 (5)
The role of DNA methylation in ovarian cancer chemoresistance: A narrative review
Background and Aims: Ovarian cancer (OC) is the most lethal gynecological cancer. In 2018, it was responsible for over 180,000 deaths worldwide. The high mortality rate is the culmination of a lack of early diagnosis and high rates of chemotherapy resistance, which is synonymous with disease recurrence. Over the last two decades, an increasingly significant role of epigenetic mechanisms, in particular DNA methylation, has emerged. This review will discuss several of the most significant genes whose hypo/hypermethylation profiles are associated with chemoresistance. Aside from functionally elucidating and evaluating these epimutations, this review will discuss recent trials of DNA methyltransferase inhibitors (DNMTi). Finally, we will propose future directions that could enhance the feasibility of utilizing these candidate epimutations as clinical biomarkers.Methods: To perform this review, a comprehensive literature search based on our keywords was conducted across the online databases PubMed and Google Scholar for identifying relevant studies published up until August 2022.Results: Epimutations affecting MLH1, MSH2, and Ras‐association domain family 1 isoform A (DNA damage repair and apoptosis); ATP‐binding cassette subfamily B member 1 and methylation‐controlled J (drug export); secreted frizzled‐related proteins (Wnt/β‐catenin signaling), neurocalcin delta (calcium and G protein‐coupled receptor signaling), and zinc finger protein 671 all have potential as biomarkers for chemoresistance. However, specific uncertainties relating to these epimutations include histotype‐specific differences, intrinsic versus acquired chemoresistance, and the interplay with complete surgical debulking. DNMTi for chemoresistant OC patients has shown some promise; however, issues surrounding their efficacy and dose‐limiting toxicities remain; a personalized approach is required to maximize their effectiveness.Conclusion: Establishing a panel of aberrantly methylated chemoresistance‐related genes to predict chemoresponsiveness and patients' suitability to DNMTi could significantly reduce OC recurrence, while improving DNMTi therapy viability. To achieve this, a large‐scale prospective genome‐wide DNA methylation profile study that spans different histotypes, includes paired samples (before and after chemotherapy), and integrates transcriptomic and methylomic analysis, is warranted.
- 27 April 2023
- Published by Wiley in Health Science Reports
- Vol. 6 (5)
Open AccessThe role of DNA methylation in ovarian cancer chemoresistance: A narrative review
Background and Aims: Ovarian cancer (OC) is the most lethal gynecological cancer. In 2018, it was responsible for over 180,000 deaths worldwide. The high mortality rate is the culmination of a lack of early diagnosis and high rates of chemotherapy resistance, which is synonymous with disease recurrence. Over the last two decades, an increasingly significant role of epigenetic mechanisms, in particular DNA methylation, has emerged. This review will discuss several of the most significant genes whose hypo/hypermethylation profiles are associated with chemoresistance. Aside from functionally elucidating and evaluating these epimutations, this review will discuss recent trials of DNA methyltransferase inhibitors (DNMTi). Finally, we will propose future directions that could enhance the feasibility of utilizing these candidate epimutations as clinical biomarkers.Methods: To perform this review, a comprehensive literature search based on our keywords was conducted across the online databases PubMed and Google Scholar for identifying relevant studies published up until August 2022.Results: Epimutations affecting MLH1, MSH2, and Ras‐association domain family 1 isoform A (DNA damage repair and apoptosis); ATP‐binding cassette subfamily B member 1 and methylation‐controlled J (drug export); secreted frizzled‐related proteins (Wnt/β‐catenin signaling), neurocalcin delta (calcium and G protein‐coupled receptor signaling), and zinc finger protein 671 all have potential as biomarkers for chemoresistance. However, specific uncertainties relating to these epimutations include histotype‐specific differences, intrinsic versus acquired chemoresistance, and the interplay with complete surgical debulking. DNMTi for chemoresistant OC patients has shown some promise; however, issues surrounding their efficacy and dose‐limiting toxicities remain; a personalized approach is required to maximize their effectiveness.Conclusion: Establishing a panel of aberrantly methylated chemoresistance‐related genes to predict chemoresponsiveness and patients' suitability to DNMTi could significantly reduce OC recurrence, while improving DNMTi therapy viability. To achieve this, a large‐scale prospective genome‐wide DNA methylation profile study that spans different histotypes, includes paired samples (before and after chemotherapy), and integrates transcriptomic and methylomic analysis, is warranted.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Enhanced Immunogenicity of Mitochondrial-Localized Proteins in Cancer Cells
Epitopes derived from mutated cancer proteins elicit strong antitumor T-cell responses that correlate with clinical efficacy in a proportion of patients. However, it remains unclear whether the subcellular localization of mutated proteins influences the efficiency of T-cell priming. To address this question, we compared the immunogenicity of NY-ESO-1 and OVA localized either in the cytosol or in mitochondria. We showed that tumors expressing mitochondrial-localized NY-ESO-1 and OVA proteins elicit significantdly higher frequencies of antigen-specific CD8+ T cells in vivo. We also demonstrated that this stronger immune response is dependent on the mitochondrial location of the antigenic proteins, which contributes to their higher steady-state amount, compared with cytosolic localized proteins. Consistent with these findings, we showed that injection of mitochondria purified from B16 melanoma cells can protect mice from a challenge with B16 cells, but not with irrelevant tumors. Finally, we extended these findings to cancer patients by demonstrating the presence of T-cell responses specific for mutated mitochondrial-localized proteins. These findings highlight the utility of prioritizing epitopes derived from mitochondrial-localized mutated proteins as targets for cancer vaccination strategies.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Enhanced Immunogenicity of Mitochondrial-Localized Proteins in Cancer Cells
Epitopes derived from mutated cancer proteins elicit strong antitumor T-cell responses that correlate with clinical efficacy in a proportion of patients. However, it remains unclear whether the subcellular localization of mutated proteins influences the efficiency of T-cell priming. To address this question, we compared the immunogenicity of NY-ESO-1 and OVA localized either in the cytosol or in mitochondria. We showed that tumors expressing mitochondrial-localized NY-ESO-1 and OVA proteins elicit significantdly higher frequencies of antigen-specific CD8+ T cells in vivo. We also demonstrated that this stronger immune response is dependent on the mitochondrial location of the antigenic proteins, which contributes to their higher steady-state amount, compared with cytosolic localized proteins. Consistent with these findings, we showed that injection of mitochondria purified from B16 melanoma cells can protect mice from a challenge with B16 cells, but not with irrelevant tumors. Finally, we extended these findings to cancer patients by demonstrating the presence of T-cell responses specific for mutated mitochondrial-localized proteins. These findings highlight the utility of prioritizing epitopes derived from mitochondrial-localized mutated proteins as targets for cancer vaccination strategies.